Effect of riboflavin supplementation on blood pressure and possible effect modification by the MTHFR C677T polymorphism: a randomised trial in rural Gambia

Name	World Continuing Education Alliance
Activity Title	Effect of riboflavin supplementation on blood pressure and possible effect modification by the MTHFR C677T polymorphism: a randomised trial in rural Gambia
Details	AE: adverse events; BMI: body mass index; BP: blood pressure; CRF: case report forms; CTSO: clinical trial support office; DAG: data access group; DM: data manager; EGRAC: erythrocyte gluthathione reductase activation coefficient; US FNB: United States Food and Nutrition Board; FAD: flavin-adenine dinucleotide; GCP: Good Clinical Practice; HIGH: Hepcidin and Iron in Global Health; MRCG at LSHTM: Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine; MTHF: methylene tetrahydrofolate; MTHFR: methylene tetrahydrofolate reductase; QC: quality check; PI: principal investigator; REDCap: Research Electronic Data Capture; RNI: Recommended Nutrient Intake; SAE: severe adverse events; SEM: structural equation modelling; SSA: sub-Saharan Africa. Objectives Course Objective Emerging evidence links a functional polymorphism in the methylenetetrahydrofolate reductase (. This is a phase 2 recall-by-genotype randomised single-blind placebo-controlled riboflavin supplementation trial. We will use the Keneba biobank to recruit approximately 102 individuals aged between 18-70, previously genotyped for the. The study will evaluate the role of riboflavin supplementation in BP control within a population with high levels of riboflavin deficiency and will test a possible gene-nutrient interaction with the. ClinicalTrials.gov Identifier n
Competence	Public Health
Start Date	<span class="not-set">(not set)</span>
End Date	<span class="not-set">(not set)</span>
Event Time	02:30 PM
Location	World Continuing Education Alliance eLearning System
Cost (UGX)	0
CPD Points	1